TheraRadar
← Back
Data updated: Jul 17, 2026

CELLTRION, INC.

Biotech
ImmunologyOncologyCardiovascular Execution: Good

CELLTRION, INC. is a biotechnology company focused on Immunology, Oncology, Cardiovascular.

2024
Since
1
Drugs
-
Trials
2
New Drugs (2yr)

CELLTRION, INC. at a Glance

  • Fast trial execution (14 months median completion)

CELLTRION, INC.'s Key Drugs

CELLTRION, INC.'s key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CELLTRION, INC.'s Recent FDA Approvals

CELLTRION, INC. secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

STEQEYMA BLA
2025-04-30
ustekinumab-stba
1. INDICATIONS AND USAGE STEQEYMA is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis (PsO), who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) 1.1. Plaque Psoriasis (PsO) STEQEYMA is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.2. Psoriatic Arthritis (PsA) STEQEYMA is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. 1.3. Crohn's Disease (CD) STEQEYMA is indicated for the treatment of adult patients with moderately to severely active Crohn's disease. 1.4. Ulcerative Colitis STEQEYMA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
STEQEYMA BLA
2024-12-17
ustekinumab-stba
1. INDICATIONS AND USAGE STEQEYMA is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis (PsO), who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) 1.1. Plaque Psoriasis (PsO) STEQEYMA is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.2. Psoriatic Arthritis (PsA) STEQEYMA is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. 1.3. Crohn's Disease (CD) STEQEYMA is indicated for the treatment of adult patients with moderately to severely active Crohn's disease. 1.4. Ulcerative Colitis STEQEYMA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

CELLTRION, INC.'s Therapeutic Areas

CELLTRION, INC.'s approved drugs and pipeline span 5 therapeutic areas, led by Immunology and Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 58%
0 drugs Phase 3: 15 Phase 1: 3
Oncology 28%
0 drugs Phase 3: 7 Phase 1: 2
Cardiovascular 5%
0 drugs Phase 3: 1 Phase 1: 1
Gastroenterology 5%
0 drugs Phase 3: 1 Phase 1: 1
Infectious Disease 5%
0 drugs Phase 2: 1 Phase 1: 3

CELLTRION, INC.'s Top Competitors

CELLTRION, INC.'s closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Sanofi, and Bristol-Myers Squibb. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Immunology, Infectious Disease, Gastroenterology
Sanofi big-pharma
Oncology, Infectious Disease, Immunology, Cardiovascular
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Infectious Disease, Gastroenterology
Pfizer big-pharma
Oncology, Infectious Disease, Immunology
Takeda big-pharma
Immunology, Gastroenterology, Oncology, Cardiovascular

CELLTRION, INC. Pipeline Snapshot

CELLTRION, INC. has 35 active clinical programs from ClinicalTrials.gov — 24 Phase 3, 1 Phase 2 and 10 Phase 1.

24
Phase 3
1
Phase 2
10
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Immunology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 23/30 completed
  • • Speed: 14 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges